Long-Term Weight Loss Data With Saxenda Announced
New clinical trial data presented at ObesityWeek 2015 showed that treatment with Saxenda (liraglutide; Novo Nordisk) in combination with a reduced-calorie diet and increased physical activity led to significant and sustained weight loss over 3 years vs. a reduced-calorie diet and increased physical activity alone (placebo).
The 3-year extension part of the Phase 3a SCALE™ (Satiety and Clinical Adiposity: Liraglutide Evidence in Non-Diabetic and Diabetic adults) Obesity and Pre-diabetes study included 2,254 adults with obesity or who were overweight with comorbidities and had prediabetes at baseline.
RELATED: Liraglutide Linked to Greater Weight Loss Over 56 Weeks in T2DM
At Week 160, patients treated with Saxenda had an average body weight loss of 6.1% from baseline vs. 1.9% for placebo (P<0.0001). Weight loss ≥5% was seen in 49.6% of patients treated with Saxenda vs. 23.7% for placebo (P<0.0001). Data also showed 24.8% of patients lost >10% of their body weight with Saxenda vs. 9.9% with placebo (P<0.0001).
The extension trial achieved the primary endpoint showing that continued treatment with Saxenda in combination with a reduced-calorie diet and increased physical activity delayed the onset of type 2 diabetes vs. placebo.
Saxenda injection, a glucagon-like peptide-1 (GLP-1) receptor agonist, is available as prefilled multi-dose pens delivering doses of 0.6mg, 1.2mg, 1.8mg, 2.4mg, or 3mg (6mg/mL, 3mL) in 3- and 5-count cartons.
For more information call (800) 727-6500 or visit Saxenda.com.